The oral phosphodiesterase type 5 (PDE5) inhibitors have made a valuable contribution to
the treatment of erectile dysfunction (ED). PDE5 inhibitors enhance cavernosal smooth …

Abstract Phosphodiesterase type-5 inhibitor (PDE5-i) drugs were first marketed in 1998
(sildenafil) for'ondemand'treatment of male erectile dysfunction (ED) of any origin. They …

The success of sildenafil (Viagra®; Pfizer) as an oral therapy for male erectile dysfunction
(MED) has greatly stimulated interest in phosphodiesterase (PDE)-5 inhibitors. A large …

Inhibition of phosphodiesterase-5 (PDE5) reduces the degradation of cyclic guanosine
monophosphate, which allows erectile function to occur by relaxation of penile smooth …

The discovery that inhibition of phosphodiesterase-5 (PDE5) reduces the degradation of
cGMP, allowing erectile function to occur by relaxation of penile smooth muscle, represents …

Since the discovery of sildenafil in 1989 as a highly selective inhibitor of the
phosphodiesterase type-5 (PDE-5) receptor, 2 additional PDE-5 inhibitors, tadalafil and …

PDE5 inhibitors have been clearly established as first-line therapy for the treatment of
erectile dysfunction (ED). Three PDE5 inhibitors-sildenafil (Viagra®), vardenafil (Levitra®) …

PDE-5 inhibitors were originally studied in cardiovascular indications but were later
developed and approved for on-demand treatment of erectile dysfunction (ED). A few years …

Erectile dysfunction (ED) occurs in varying degrees in an estimated 20 to 30 million
American men and is associated with adverse effects on quality of life; particularly personal …

Abstract The phosphodiesterase-5 inhibitors (PDE5i) sildenafil, vardenafil, and tadalafil are
considered first-line therapy for the treatment of patients with erectile dysfunction (ED). In …